Posted in | News | Nanomedicine | Nanomaterials

Peer-Reviewed Nanomaterials and Nanotechnology Journal Receives 0.949 Impact Factor

Nanomaterials and Nanotechnology journal has received its first Journal Impact Factor of 0.949 as of July 29th, 2014. Up to this date, all journal's Volumes have been indexed in SCIE and Current Contents databases, as well as in Scopus.

Nanomaterials and Nanotechnology Journal Receives 0.949 Impact Factor" />

Nanomaterials and Nanotechnology journal, currently in its 4th Volume, is an international, scientific and peer-reviewed journal published online under Open Access, hence all the journal's articles are free to be read, shared and downloaded with no restrictions.

Under the editorship of Dr. Paola Prete, Institute for Microelectronics and Microsystems, National Research Council (Italy), the journal has grown into an ambitious and successful project, regularly publishing new challenges in the nanotechnology field, both for application development and for basic research. Since its launch in 2011, Nanomaterials and Nanotechnology has featured research from experts in the field such as C. N. R. Rao and Stephen Pearton, also members of the journal's Editorial Board.

Following the success of Nanomaterials and Nanotechnology and the team's active engagement in the nano field, clear evidence pointing towards the need for a new project emerged, resulting in the launch of Nanobiomedicine journal - with the aim of targeting professionals in this dynamic field of research.

In the words of its Editors-in-Chief, Dr. Winston Patrick Kuo from the Harvard Medical School (USA), and Dr. Markus Dettenhofer, CEITEC Executive Director (Chech Republic),
'Nanobiomedicine is a new, open access scientific journal that will publish up-to-date expert reviews, scientific manuscripts, technology reports, perspectives, opinions and editorials in the rapidly emerging field of nanotechnology and biomedical research. It will enable the clinical and scientific community to publish their latest ground-breaking research, up-to-date reviews, perspectives and opinions quickly and at the same token, readers around the globe will be able access them online as soon as they are published.'

When asked about the Editorial Board's ultimate goal with this journal, Dr. Kuo highlights the following,
'The Editorial Board will play a key role in developing collaborations/partnerships with international societies through conferences, meetings, webinars they will be attending, which will include scientific experts who understand how discovery moves from lab to the market and to attract contributors and participation from a more global audience.
These experts will serve as the central hub of the nanotechnology and biomedical research community for the latest advances and provide us guidance. We will be reaching out to scientists, researchers and clinicians from academia and industry who are involved in research and development of nano-translational and clinical applications that addresses the challenges and advances in diagnostics to delivery of therapeutics to monitoring of human diseases and other related areas of life and health sciences. The Editorial Board will provide opinion and perspectives that cover a broad range of topics in the field of nanotechnology and biomedical research, and at times selected themes and special issues. '

The journal's Editorial Board includes reputable scientists such as Marko Loncar (Harvard University, USA), Alexander Marcus Seifalian (University College London, UK), Molly S. Shoichet (University of Toronto, Canada), Utkan Demirci (Stanford University, USA), Ali Khademhosseini (Harvard Medical School, USA), and many others.

We invite all interested researchers active in the field of nanobiomedicine to submit their research papers to this new exciting journal. The submission can be completed at the journal's official homepage at intechopen.com. All accepted papers will be published for free.

To contact the Nanomaterials and Nanotechnology's team or its Editor-in-Chief, please write to [email protected]. For all information regarding Nanobiomedicine, contact us at [email protected].

About the publisher:
InTech is an open access publisher within the fields of Science, Technology and Medicine. Established in 2004, the company is one of the earliest pioneers of open access and has since become one of the fastest growing publishers in the world today.

With its headquartes located in Europe, InTech works with authors, editors and societies on a global scale to publish the latest advances in theories and application of some of the most exciting research areas in STM, all to be accessed freely online.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.